3-(aminomethyl)-1,4-naphtho<1,2-b>dioxan | 113777-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(aminomethyl)-1,4-naphtho<1,2-b>dioxan
• 英文别名: 2,3-Dihydrobenzo[h][1,4]benzodioxin-3-ylmethanamine
• CAS: 113777-38-1
• 化学式: C₁₃H₁₃NO₂
• 分子量: 215.252
• InChiKey: PIMFDPOFTJGGFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(aminomethyl)-1,4-naphtho<1,2-b>dioxan 、 N-<4-(tosyloxy)butyl>-3,3-tetramethyleneglutarimide 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以48.5%的产率得到8-(4-{[(2,3-dihydronaphtho[1,2-b]dioxin-3-yl)methyl]amino}butyl)-8-azaspiro[4.5]decane-7,9-dione
  参考文献：
  名称：

  Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor

  摘要：

  A conformational study of four 5-HT1A (serotonin) receptor ligands ((R-(-)-methiothepin, spiperone, (S)-(-)-propranolol, and buspirone) led to the definition of a pharmacophore and a three-dimensional map of the 5-HT1A antagonist recognition site. These models were used to design new compounds and successfully predict their potency, stereospecificity, and selectivity. For example, 8-[4-[(1,4-benzodioxan-2-ylmethyl)amino] butyl]-8-azaspiro[4.5]decane-7,9-dione (1, MDL 72832) has nanomolar affinity (pIC50 = 9.14) for the 5-HT1A binding site in rat frontal cortex. As predicted, the S-(-) enantiomer of 1 was more active than its R-(+) enantiomer (pIC50 = 9.21 and 7.66, respectively) and a naphthalene analogue of 1 displayed the expected improved selectivity.

  DOI：

  10.1021/jm00401a007
• 作为产物：
  描述：

  1,2-dihydroxynaphthlene dipotassium salt 在 lithium aluminium tetrahydride 作用下， 生成 3-(aminomethyl)-1,4-naphtho<1,2-b>dioxan
  参考文献：
  名称：

  表氯醇合成2-氨基甲基萘二恶烷基衍生物的再研究

  摘要：

  已经重新研究了推定的具有药理活性的2-取代的萘二氧杂戊基衍生物的合成，并且明确地重新分配了关键中间体的结构。

  DOI：

  10.1039/c39860001432

文献信息

• Novel derivatives of 1,7'-[imidazo-[1,2-a]pyridine]5'-(6'H)ones
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0375819A1

  公开（公告）日：1990-07-04

  This invention relates to novel derivatives of 1,7′-[imidazo-[1,2-a]pyridine]5′-(6′H)ones, to the method for their preparation and to their use as anti-­hypertensive, anxiety, anti-depressant and anti-migraine agents, and to their use as appetite regulators useful for the treatment of anorexia and obesity.

  本发明涉及 1,7′-[咪唑并[1,2-a]吡啶]5′-(6′H)-1 的新型衍生物、其制备方法和用作抗高血压、抗焦虑、抗抑郁和抗偏头痛药物，以及用作治疗厌食症和肥胖症的食欲调节剂。
• Use of certain 1,2-benzoisothiazol-3(2H)-1,1-dioxide derivatives in the treatment of depression and mania
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0492021A1

  公开（公告）日：1992-07-01

  This invention relates to the manufacture of certain aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives for their use as medicaments in the treatment of depression and mania.

  本发明涉及某些芳香族 2-氨基烷基-1,2-苯并异噻唑-3(2H)-1,1-二氧化物衍生物的生产，这些衍生物可用作治疗抑郁症和狂躁症的药物。
• Glutarimide antianxiety and antihypertensive agents
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0170213B1

  公开（公告）日：1990-01-10
• Derivatives of 1,7'-(imidazo-(1,2-a)pyridine) 5'-(6'H) ones and process for their preparation
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0375536B1

  公开（公告）日：1994-07-13
• USE OF CERTAIN GLUTARIMIDE DERIVATIVES IN THE TREATMENT OF DEPRESSION AND MANIA
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0564520A1

  公开（公告）日：1993-10-13